Fig. 6: IL-1R- or NLRP3- inhibition in KrasG12D mice leads to reduced myeloproliferation.
From: Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
a The percentage of hematocrit in PB of vehicle-treated KrasG12D (n = 15), Anakinra-treated KrasG12D (n = 10) or MCC950-treated KrasG12D (n = 15) BM mice. Both Anakinra and NLRP3 inhibitor (MCC950) treatment started 3 weeks post-tamoxifen and ended a day before sacrificing the mice (treatment was in total for 4 weeks). b The concentrations of hemoglobin in PB of vehicle-treated KrasG12D (n = 15), Anakinra-treated KrasG12D (n = 10) or MCC950-treated KrasG12D (n = 15) BM mice. c The percentage of immature red blood cells observed in PB of vehicle-treated KrasG12D (n = 15), Anakinra-treated KrasG12D (n = 10) or MCC950-treated KrasG12D (n = 15) BM mice. d Shown are the number of platelets in PB of vehicle-treated KrasG12D (n = 15), Anakinra-treated KrasG12D (n = 10) or MCC950-treated KrasG12D (n = 15) BM mice. e The number of blast cells counted in BM isolated from vehicle-treated KrasG12D (n = 5), Anakinra-treated KrasG12D (n = 6) or MCC950-treated KrasG12D (n = 15) BM mice. The counts represent percentage of 100 analyzed cells. f The number of spleen follicles counted in spleens isolated from vehicle-treated KrasG12D (n = 5), Anakinra-treated KrasG12D (n = 6) or MCC950-treated KrasG12D (n = 15) BM mice, per 1 high power field (HPF). g The histogram shows mean fluorescence intensity (MFI) for IL-1β in BMDCs of vehicle-treated KrasG12D, Anakinra-treated KrasG12D or MCC950-treated KrasG12D BM mice. One representative experiment from three experiments is shown. h The graph displays the fold change of IL-1β expression as measured by flow cytometry in BMDCs of vehicle-treated KrasG12D (n = 15), Anakinra-treated KrasG12D (n = 10) or MCC950-treated KrasG12D (n = 15) BM mice, normalized to vehicle-treated KrasG12D in both stimulation conditions. i FlowSOM-guided metaclustering of CD45+ BM cells (gated on live/single cells/CD45+) per condition: vehicle-treated KrasG12D (n = 4), Anakinra-treated KrasG12D (n = 5) or MCC950-treated KrasG12D (n = 5) BM mice. j Frequency of FlowSOM-guided mature neutrophils cluster among CD45+ BM cells in vehicle-treated KrasG12D (n = 4), Anakinra-treated KrasG12D (n = 5) or MCC950-treated KrasG12D (n = 5) BM mice. All data are shown as mean ± SEM.
